Bulletin
Investor Alert

Teva Pharmaceutical Industries Ltd. ADR

NYS: TEVA

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Nov 25, 2022, 3:51 p.m.

/zigman2/quotes/205657894/composite

$

8.94

Change

+0.07 +0.79%

Volume

Volume 5,109

Quotes are delayed by 20 min

/zigman2/quotes/205657894/composite

Previous close

$ 8.80

$ 8.87

Change

+0.07 +0.80%

Day low

Day high

$8.74

$8.95

Open

52 week low

52 week high

$6.78

$11.34

Open

Company Description

Teva Pharmaceutical Industries Ltd. engages in the development and production of medicines. Its products include medicines for cardiovascular diseases, pain relievers, obesity, cancer and supportive care, infectious diseases and human immunodeficiency viruses, and colds and coughs. The firm operates...

Teva Pharmaceutical Industries Ltd. engages in the development and production of medicines. Its products include medicines for cardiovascular diseases, pain relievers, obesity, cancer and supportive care, infectious diseases and human immunodeficiency viruses, and colds and coughs. The firm operates through following geographical segments: North America, Europe and International Markets. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

Valuation

P/E Current

24.70

P/E Ratio (without extraordinary items)

22.05

Price to Sales Ratio

0.58

Price to Book Ratio

0.93

Price to Cash Flow Ratio

3.78

Enterprise Value to EBITDA

7.04

Enterprise Value to Sales

2.03

Total Debt to Enterprise Value

0.74

Efficiency

Revenue/Employee

1,363,661.00

Income Per Employee

35,884.00

Receivables Turnover

3.55

Total Asset Turnover

0.33

Liquidity

Current Ratio

1.14

Quick Ratio

0.79

Cash Ratio

0.20

Profitability

Gross Margin

47.10

Operating Margin

19.36

Pretax Margin

4.15

Net Margin

2.63

Return on Assets

0.87

Return on Equity

4.20

Return on Total Capital

8.67

Return on Invested Capital

1.30

Capital Structure

Total Debt to Total Equity

229.31

Total Debt to Total Capital

69.63

Total Debt to Total Assets

49.44

Long-Term Debt to Equity

214.37

Long-Term Debt to Total Capital

65.10

Officers and Executives

Name Age Officer Since Title
Mr. Kåre Schultz 59 2017 President, Chief Executive Officer & Director
Dr. Eric Drapé 59 2013 Executive Vice President-Global Operations
Mr. Eli Kalif 48 2019 Chief Financial Officer & Executive Vice President
Dr. Eric A. Hughes - 2022 Chief Medical Officer, Executive VP-Global R&D
Mr. John Nason - 2015 President-Biologics Operations

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
05/10/2018 Bridger Management LLC
Director
250,000   Acquisition at $19.32 per share. 4,830,000
05/09/2018 Bridger Management LLC
Director
500,000   Acquisition at $19.21 per share. 9,605,000
/news/latest/company/us/teva

MarketWatch News on TEVA

  1. Teva names former Sandoz chief Richard Francis as new CEO

    7:16 a.m. Nov. 21, 2022

    - Steve Gelsi

  2. Teva Pharmaceutical names pharma exec Richard Francis and president and CEO

    7:05 a.m. Nov. 21, 2022

    - Steve Gelsi

  3. New Teva CEO Richard Francis was CEO of Sandoz and Biogen exec

    7:05 a.m. Nov. 21, 2022

    - Steve Gelsi

  4. Teva CEO Kåre Schultz to retire on Dec. 31

    7:05 a.m. Nov. 21, 2022

    - Steve Gelsi

  5. Teva Pharmaceutical downgraded to underweight from neutral at J.P. Morgan

    6:45 a.m. Nov. 14, 2022

    - Tomi Kilgore

  6. Teva Is 'on the Way' to Leaving Opioid Litigation Behind, CEO Says

    11:28 a.m. Nov. 3, 2022

    - Barron's Online

  7. Teva Pharmaceutical upgraded to buy from neutral at BofA Securities

    8:44 a.m. Aug. 5, 2022

    - Tomi Kilgore

  8. $4.4 Billion Opioid Settlement Gives Teva Stock a Boost

    2:32 a.m. July 28, 2022

    - Barron's Online

  9. Teva Stock Soars After Reaching $4.25 Billion Opioid Settlement

    5:14 a.m. July 27, 2022

    - Barron's Online

  10. Teva to pay $75 mln over 15 years to settle opioid claims from W. Va., plus pay $8 mln in legal fees

    8:46 a.m. May 25, 2022

    - Steve Gelsi

  11. Teva settlement with W. Va. also includes $27 mln worth of generic Narcan over 10 years

    8:46 a.m. May 25, 2022

    - Steve Gelsi

  12. W. Va. says Teva opioid agreement consistent with previously announced settlements

    8:46 a.m. May 25, 2022

    - Steve Gelsi

  13. Teva Pharmaceutical upgraded to neutral from underperform at BofA Securities

    8:36 a.m. May 17, 2022

    - Tomi Kilgore

  14. Pfizer to Buy Biohaven Pharmaceuticals for $11.6 Billion

    9:06 a.m. May 10, 2022

    - Barron's Online

  15. Loading more headlines...
/news/nonmarketwatch/company/us/teva

Other News on TEVA

  1. Teva Pharmaceutical Names Richard Francis as CEO

    10:13 a.m. Nov. 21, 2022

    - Colin Kellaher

  2. Opioid reversal agent naloxone approvable for OTC use – FDA

    1:37 p.m. Nov. 15, 2022

    - Seeking Alpha

  3. Top 5 3rd Quarter Trades of DSC Advisors, L.P.

    8:00 a.m. Nov. 15, 2022

    - GuruFocus.com

  4. Teva slips as JPMorgan downgrades on growth concerns

    9:01 a.m. Nov. 14, 2022

    - Seeking Alpha

  5. BECK MACK & OLIVER LLC Buys 2, Sells 3 in 3rd Quarter

    6:00 p.m. Nov. 10, 2022

    - GuruFocus.com

  6. Teva Pharmaceutical to Replace CEO Kare Schultz

    4:24 p.m. Nov. 3, 2022

    - Jared S. Hopkins

  7. 10-Q: TEVA PHARMACEUTICAL INDUSTRIES LTD

    4:22 p.m. Nov. 3, 2022

    - Edgar Online - (EDG = 10Q, 10K)

  8. Loading more headlines...

At a Glance

Teva Pharmaceutical Industries Ltd.

124 Dvora HaNevi'a Street

Tel Aviv, TA 6944020

Phone

972 39148213

Industry

Pharmaceuticals

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2022

Revenue

$51.19B

Net Income

$1.35B

Employees

37,537

/news/pressrelease/company/us/teva

Press Releases on TEVA

  1. Teva Finalizes Nationwide Opioid Settlement Terms

    8:30 a.m. Nov. 22, 2022

    - BusinessWire - BZX

  2. Teva Announces Appointment of Richard Francis as President and CEO

    7:00 a.m. Nov. 21, 2022

    - BusinessWire - BZX

  3. Learn to Evaluate Teva Pharmaceutical (TEVA) using the Charts

    3:09 a.m. Nov. 17, 2022

    - Stock Traders Daily

  4. How To Trade Teva Pharmaceutical TEVA

    10:59 a.m. Nov. 7, 2022

    - Stock Traders Daily

  5. Teva Reports Third Quarter 2022 Financial Results

    6:00 a.m. Nov. 3, 2022

    - BusinessWire - BZX

  6. Teva Pharmaceutical TEVA Investment Report

    6:16 p.m. Oct. 28, 2022

    - Stock Traders Daily

  7. Teva Pharmaceutical TEVA Trading Report

    2:07 a.m. Oct. 19, 2022

    - Stock Traders Daily

  8. Teva Pharmaceutical TEVA Investment Analysis and Advice

    9:08 a.m. Oct. 9, 2022

    - Stock Traders Daily

  9. Teva Pharmaceutical (TEVA) Trading Report

    4:31 p.m. Sept. 29, 2022

    - Stock Traders Daily

  10. Loading more headlines...
Link to MarketWatch's Slice.